Skip to content
2000
Volume 19, Issue 33
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Advances in risk prediction are necessary to stem the tide of the increasing incidence of global cardiovascular disease. Newly discovered biomarkers are needed for primary and secondary prevention and will undoubtedly play a major role in drug development programs and monitoring of treatment efficacy. The combination of improved -omics technologies and the investigation of relatively untapped sources of biomarkers will likely result in risk algorithms that will add value on top of the traditional risk factors. New sources of biomarkers are being explored with encouraging results. These include microvesicles, microRNAs, circulating cells and atherosclerotic plaques. We will review these sources for their potential for new biomarkers. Furthermore, the major impact of advances in genetics on risk prediction and biomarker development programs will be discussed.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/13816128113199990371
2013-10-01
2025-04-23
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/13816128113199990371
Loading

  • Article Type:
    Research Article
Keyword(s): Atherosclerosis; biomarkers; cardiovascular; discovery; drug; novel
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test